Kiora Pharmaceuticals (Kiora Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of May. 01, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2024-05-01), Kiora Pharmaceuticals's share price is $0.52. Kiora Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.76. Hence, Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

KPRX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 26.12
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Kiora Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.34. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.76.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 68.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 56.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 33.40% per year.

During the past 12 years, Kiora Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 68.60% per year. The lowest was -50.40% per year. And the median was 37.80% per year.

Kiora Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Kiora Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Kiora Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Kiora Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.52	/	-2.759
	=

Kiora Pharmaceuticals's Share Price of today is $0.52.
Kiora Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.76.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Kiora Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiora Pharmaceuticals (Kiora Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

7EY0:Germany

Address

332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024

Website

https://www.kiorapharma.com

Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.

Executives

Carmine N. Stengone	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Melissa Tosca	officer: EVP of Finance	C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Susan L. Drexler	officer: Interim CFO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
David Hollander	director	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Brian M. Strem	director, officer: President and CEO	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Eric Joseph Daniels	officer: Chief Development Officer	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Aron Shapiro	director	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Kenneth L Gayron	director	75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr	officer: Acting CEO	C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Bernard Malfroy-camine	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110
Thomas Hancock	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110